

of adding 1–BP to the CAA section 112(b)(1) HAP list.

V. Statutory and Executive Order Review

Additional information about this Executive Order can be found at <https://www.epa.gov/laws-regulations/laws-and-executive-orders>.

A. Executive Order 12866: Regulatory Planning and Review and Executive Order 13563: Improving Regulation and Regulatory Review

This action is a significant regulatory action that was submitted to the Office of Management and Budget (OMB) for review because it raises novel legal or policy issues. Any changes made in response to OMB recommendations have been documented in the docket.

Andrew Wheeler,
Administrator.

[FR Doc. 2020–13145 Filed 6–17–20; 8:45 am]

BILLING CODE 6560–50–P

FARM CREDIT SYSTEM INSURANCE CORPORATION

Regular Meeting; Farm Credit System Insurance Corporation Board

AGENCY: Farm Credit System Insurance Corporation.

ACTION: Notice, regular meeting.

SUMMARY: Notice is hereby given, in accordance with the provisions of Article VI of the Bylaws of the Farm Credit System Insurance Corporation (FCSIC), that a regular meeting of the Board of Directors of FCSIC will be held June 25, 2020, at 10 a.m. EDT, until such time as the Board may conclude its business. *Note: Because of the COVID–19 pandemic, we will conduct the board meeting virtually. If you would like to observe the open portion of the virtual meeting, see instructions below for board meeting visitors.*

Attendance: To observe the open portion of the virtual meeting, go to FCSIC.gov, select “News & Events,” then “Board Meetings.” There you will find a description of the meeting and “Instructions for board meeting visitors.” See **SUPPLEMENTARY**

INFORMATION for further information about attendance requests.

FOR FURTHER INFORMATION CONTACT: Dale Aultman, Secretary to the Board of the Farm Credit System Insurance Corporation (703) 883–4009. TTY is (703) 883–4056.

SUPPLEMENTARY INFORMATION: Parts of this meeting of the Board will be open to the public, and parts will be closed. If you wish to observe the open portion, follow the instructions above in the “Attendance” section at least 24 hours before the meeting. *Please note that this meeting begins at 10:00 a.m. EDT with a session that is closed to the public. You may join this meeting at 11:15 a.m. EDT. We will begin the open session promptly at 11:30 a.m. EDT.*

Assistance: If you need assistance for accessibility reasons or if you have any questions, contact Dale Aultman, Secretary to the Farm Credit Administration Board, at (703) 883–4009. The matters to be considered at the meeting are as follows:

A. Closed Session—Risk Management Reports

- FCSIC Report on Insurance Risk/Premium Risk Factors

B. Open Session

Approval of Minutes

- March 12, 2020

C. Quarterly Business Reports

- FCSIC Financial Report
- Report on Insured Obligations
- Report on Annual Performance Plan

D. New Business

- Mid-Year Review of Insurance Premium Rates

Dated: June 15, 2020.

Dale Aultman,

Secretary, Farm Credit System Insurance Corporation.

[FR Doc. 2020–13178 Filed 6–17–20; 8:45 am]

BILLING CODE 6705–01–P

PLACE: 1050 First Street NE, Washington, DC (This meeting will be a virtual meeting).

STATUS: This meeting will be closed to the public.

MATTERS TO BE CONSIDERED: Compliance matters pursuant to 52 U.S.C. 30109. Matters concerning participation in civil actions or proceedings or arbitration.

* * * * *

CONTACT PERSON FOR MORE INFORMATION: Judith Ingram, Press Officer; Telephone: (202) 694–1220.

Vicktoria J. Allen,

Acting Deputy Secretary of the Commission.

[FR Doc. 2020–13303 Filed 6–16–20; 4:15 pm]

BILLING CODE 6715–01–P

FEDERAL TRADE COMMISSION

Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination—on the dates indicated—of the waiting period provided by law and the premerger notification rules. The listing for each transaction includes the transaction number and the parties to the transaction. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

EARLY TERMINATIONS GRANTED MAY 1, 2020 THRU MAY 31, 2020

05/01/2020

| | | |
|----------------|---|---|
| 20201000 | G | The Carle Foundation; Advocate Aurora Health, Inc.; The Carle Foundation. |
|----------------|---|---|

05/04/2020

| | | |
|----------------|---|--|
| 20200999 | G | TPG Partners VIII, L.P.; LifeStance Health, LLC; TPG Partners VIII, L.P. |
| 20201001 | G | Quincy Health, LLC; Quorum Health Corp.; Quincy Health, LLC. |

EARLY TERMINATIONS GRANTED MAY 1, 2020 THRU MAY 31, 2020—Continued

| | | |
|-------------------|---|---|
| 20201002 | G | Mr. Len Blavatnik; DigitalOcean Holdings, Inc.; Mr. Len Blavatnik. |
| 20201003 | G | Reyes Holdings, L.L.C.; Thomas J. Louderback; Reyes Holdings, L.L.C. |
| 20201005 | G | Providence Equity Partners VIII L.P.; OUTFRONT Media Inc.; Providence Equity Partners VIII L.P. |
| 20201006 | G | Ares Special Opportunities Fund (Offshore), L.P.; OUTFRONT Media Inc.; Ares Special Opportunities Fund (Offshore), L.P. |
| 05/05/2020 | | |
| 20191732 | S | AbbVie Inc.; Allergan plc; AbbVie Inc. |
| 05/06/2020 | | |
| 20200992 | G | Starwood Opportunity Fund XI Global, L.P.; Extended Stay America, Inc.; Starwood Opportunity Fund XI Global, L.P. |
| 20201008 | G | ProAssurance Corporation; Norcal Mutual Insurance Company; ProAssurance Corporation. |
| 05/11/2020 | | |
| 20201012 | G | IIF US Holding LP; Xcel Energy Inc.; IIF US Holding LP. |
| 20201013 | G | Eros International plc; STX Filmworks, Inc.; Eros International plc. |
| 20201014 | G | Artur Bergman; Fastly, Inc.; Artur Bergman. |
| 20201016 | G | Turning Point Brands, Inc.; Standard General Offshore Fund Ltd.; Turning Point Brands, Inc. |
| 20201023 | G | KKR Americas Fund XII, L.P.; US Foods Holding Corp.; KKR Americas Fund XII, L.P. |
| 20201024 | G | Flexpoint Fund IV-A, L.P.; TigerRisk Partners LLC; Flexpoint Fund IV-A, L.P. |
| 05/13/2020 | | |
| 20201025 | G | LS Power Equity Partners IV, L.P.; Siemens Aktiengesellschaft; LS Power Equity Partners IV, L.P. |
| 05/14/2020 | | |
| 20201021 | G | Ingredion Incorporated; PureCircle Limited; Ingredion Incorporated. |
| 05/19/2020 | | |
| 20201034 | G | Wellspring Capital Partners VI, L.P.; Merit Mezzanine Fund VI, L.P.; Wellspring Capital Partners VI, L.P. |
| 20201035 | G | Cognizant Technology Solutions Corporation; William C. Ross, Jr. and Peri Ross; Cognizant Technology Solutions Corporation. |
| 20201039 | G | Nemo Investor Aggregator, Ltd.; OneSpaWorld Holdings Limited; Nemo Investor Aggregator, Ltd. |
| 20201042 | G | TPG Inertia Holdings, LP; Moshe Yanai; TPG Inertia Holdings, LP. |
| 05/20/2020 | | |
| 20201036 | G | Adam D'Angelo; Quora, Inc.; Adam D'Angelo. |
| 05/21/2020 | | |
| 20200939 | G | WillScot Corporation; Mobile Mini, Inc.; WillScot Corporation. |
| 05/26/2020 | | |
| 20201040 | G | GHO Capital Fund II LP; X-Co Holdings, LP; GHO Capital Fund II LP. |
| 20201044 | G | Royal Dutch Shell plc; National Fuel Gas Company; Royal Dutch Shell plc. |
| 20201045 | G | National Fuel Gas Company; Royal Dutch Shell plc; National Fuel Gas Company. |
| 20201050 | G | USI Advantage Corp.; Associated Banc-Corp.; USI Advantage Corp. |
| 20201053 | G | Aves IA Infrastructure Limited Partnership; Newco LLC; Aves IA Infrastructure Limited Partnership. |
| 20201054 | G | Aflac Incorporated; Zurich Insurance Group Ltd.; Aflac Incorporated. |
| 20201056 | G | Clayton, Dubilier & Rice Fund X, L.P.; Randal D. Boyd; Clayton, Dubilier & Rice Fund X, L.P. |
| 20201061 | G | Change Healthcare Inc.; National Health Coalition, Inc.; Change Healthcare Inc. |
| 20201063 | G | Lyndon Lea; Prism Data, LLC; Lyndon Lea. |
| 05/27/2020 | | |
| 20201046 | G | Halmont Properties Corporation; TerraForm Power NY Holdings, Inc.; Halmont Properties Corporation. |
| 20201047 | G | Brookfield Renewable Partners L.P.; TerraForm Power NY Holdings, Inc.; Brookfield Renewable Partners L.P. |

FOR FURTHER INFORMATION CONTACT:
Theresa Kingsberry (202-326-3100),

Program Support Specialist, Federal
Trade Commission Premerger

Notification Office, Bureau of
Competition, Room CC-5301,
Washington, DC 20024.

By direction of the Commission.

April J. Tabor,
Secretary.

[FR Doc. 2020–13109 Filed 6–17–20; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2019–N–3077]

Agency Information Collection Activities; Proposed Collection; Comment Request; Obtaining Information To Understand Challenges and Opportunities Encountered by Compounding Outsourcing Facilities

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with FDA research in obtaining information from pharmacists and other management at outsourcing facilities as well as at related compounding businesses to support a comprehensive analysis of the outsourcing facility sector that will inform ongoing FDA work in this area.

DATES: Submit either electronic or written comments on the collection of information by August 17, 2020.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before August 17, 2020. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of August 17, 2020. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.
 - If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA–2019–N–3077 for "Agency Information Collection Activities; Obtaining Information to Understand Challenges and Opportunities Encountered by Compounding Outsourcing Facilities." Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states

"THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRASStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3521), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice